The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: The GUSTO-IIb ECG Core Laboratory experience - 17/08/11
, Yuling Fu, MD b, Anatoly Langer, MD, FACC a, Aiala Barr, PhD c, Mary Tan, BSc a, Galen S. Wagner, MD, FACC d, Alejandro Barbagelata, MD e, Elena B. Sgarbossa, MD f, Yochai Birnbaum, MD, FACC e, Christopher B. Granger, MD, FACC d, Robert M. Califf, MD, FACC d, Frans Van de Werf, MD, FACC g, Eric J. Topol, MD, FACC h, Paul W. Armstrong, MD, FACC bfor the GUSTO-IIb Investigatorsi
Résumé |
Background |
Prior research suggests that patients may be entered into clinical trials with different electrocardiographic (ECG) findings than specified by study protocol criteria; the extent and impact of this variability in a large-scale trial have not been previously described.
Methods |
We evaluated the relationship between case report form (CRF) categorization of the admission ECG and a Core Laboratory and subsequent outcome in a retrospective analysis of a trial of patients with acute ischemia and a broad spectrum of ECG changes (the GUSTO-IIb trial).
Results |
In 11037 patients with CRF information and an interpretable ECG, there was agreement in 89.1% of ST-elevation and 81.9% of non–ST-elevation cases. Among patients designated as having no ST elevation on the CRF, 1-year mortality rates were significantly higher in the subgroup of patients with Core Laboratory–determined ST elevation as compared with those where both the CRF and Core Laboratory classification were in agreement (8.8% vs 6.8%, P = .0093). Among patients designated as having ST elevation by the CRF, 1-year mortality rates were similar in both the subgroup of patients with and without Core Laboratory agreement (7.7% vs 8.2%, P = .72).
Conclusions |
These findings have important implications for clinicians in routine practice because even a simple evaluation (presence or absence of ST elevation) on the admission ECG was often discordant and was associated with adverse clinical outcome.
Le texte complet de cet article est disponible en PDF.Plan
| The GUSTO-IIb trial was supported by Guidant Corporation, Redwood City, CA, and Ciba-Geigy, Summit, New Jersey, NJ. Guest editor of this manuscript is Raymond G. Gibbons, MD. |
Vol 152 - N° 2
P. 277-284 - août 2006 Retour au numéro
Article précédent
- ST-segment depression in non–ST elevation acute coronary syndromes: Quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification
- Andrew T. Yan, Raymond T. Yan, Mary Tan, Chi-Ming Chow, David H. Fitchett, Alina A. Georgescu, Quamrul Hassan, Janna Luchansky, Anatoly Langer, Shaun G. Goodman, for the Canadian ACS Registry Investigators
- Antecedent left ventricular mass and infarct size in ST-elevation myocardial infarction
- Zaza Iakobishvili, Vladimir Danicek, Avital Porter, Shula Imbar, David Brosh, Alexander Battler, David Hasdai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?